C84.79
Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Anaplastic large cell lymphoma, ALK-negative (ICD-10 code C84.79), is a rare form of non-Hodgkin lymphoma. It is a type of blood cancer characterized by abnormal growth of lymphocytes, a type of white blood cell involved in the immune response. Unlike some other lymphomas, this specific subtype does not express the ALK protein, which has implications for the disease's behavior and treatment options. This lymphoma can occur in various extranodal and solid organ sites, meaning it can develop outside the lymph nodes, affecting organs such as the skin, liver, or lungs. Its relatively rare occurrence and variable presentation pose challenges for diagnosis and management.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal cell growth Previous exposure to certain chemicals or radiation Immunosuppressive states, such as in organ transplant recipients Viral infections, including certain cases linked to viruses like Epstein-Barr virus (EBV)
Key Symptoms: Swelling or painless lumps in the lymph nodes or affected organs Unexplained weight loss Persistent fever Night sweats Fatigue or weakness Organ-specific symptoms, such as jaundice if the liver is involved, or coughing if lungs are affected
Diagnostic & Treatment
Diagnosis Path: Diagnosis of anaplastic large cell lymphoma, ALK-negative, involves a combination of clinical evaluation and laboratory tests. Typically, healthcare providers perform a biopsy of the affected tissue to examine the cancer cells under a microscope. Immunohistochemistry tests are used to determine the presence or absence of ALK protein, confirming the ALK-negative status. Imaging studies like CT, PET, or MRI scans help identify the extent and locations of the disease. Blood tests may also be conducted to assess overall health and organ function. A comprehensive diagnosis ensures accurate disease classification, which is crucial for establishing an effective treatment plan.
Treatment Protocols: Treatment strategies for ALK-negative anaplastic large cell lymphoma often include chemotherapy, targeted therapy, and, in some cases, stem cell transplantation. Chemotherapy regimens typically involve multiple agents administered over several months to destroy cancerous cells. Targeted therapies, such as monoclonal antibodies or other agents aimed at specific markers on cancer cells, may be used based on the individual case. Radiation therapy might be employed for localized disease. The approach depends on the disease's stage, location, and the patient's overall health. Continued research seeks to improve outcomes and develop personalized treatment options for this rare lymphoma subtype.
Clinical Advice & FAQs
Billing Guidance
Is C84.79 a billable ICD-10 code?
Yes, C84.79 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C84.79?
Clinical documentation must specify the nature of Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference